Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...

Bristol Myers Squibb (BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company dedicated to developing innovative therapies for ...